nasdaq:ccxi
|
https://www.indeed.com/cmp/chemocentryx
|
Aug 29th, 2022 12:00AM
|
Open
|
ChemoCentryx
|
|
Pharmaceutical & Biotechnology
|
ChemoCentryx is a biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer, primarily focused on orphan and rare diseases. We balance our passion for science with the deep-seated belief that patients suffering from serious diseases deserve more than incremental improvements to the length and quality of their lives.
As a clinical-stage company with a broad portfolio of therapeutics in areas such as orphan and rare diseases, chronic kidney disease, immuno-oncology and inflammatory and autoimmune diseases, we push ourselves beyond “good enough” and strive for a totally new way of healing.
Discrete chemokine or chemoattractant receptors play a specific role in how certain diseases progress. So, each of our drug candidates focuses on a specific chemokine or chemoattractant receptor that blocks the negative inflammatory or suppressive response driven by that particular receptor, while leaving the rest of the immune system intact.
We are passionate about the science underlying the chemoattractant network. More than that, though, we are passionate about the opportunity it holds to provide better medicines for better lives.
|
|
|
|
|
|
3.30
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3.00
|
3.00
|
4.00
|
4.50
|
3.00
|
3.50
|
3.50
|
|
|
|
|
|
|
|
|
|
Aug 29th, 2022 11:40AM
|
Aug 29th, 2022 11:40AM
|
ChemoCentryx
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nasdaq:ccxi
|
https://www.indeed.com/cmp/chemocentryx
|
Aug 28th, 2022 12:00AM
|
Open
|
ChemoCentryx
|
|
Pharmaceutical & Biotechnology
|
ChemoCentryx is a biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer, primarily focused on orphan and rare diseases. We balance our passion for science with the deep-seated belief that patients suffering from serious diseases deserve more than incremental improvements to the length and quality of their lives.
As a clinical-stage company with a broad portfolio of therapeutics in areas such as orphan and rare diseases, chronic kidney disease, immuno-oncology and inflammatory and autoimmune diseases, we push ourselves beyond “good enough” and strive for a totally new way of healing.
Discrete chemokine or chemoattractant receptors play a specific role in how certain diseases progress. So, each of our drug candidates focuses on a specific chemokine or chemoattractant receptor that blocks the negative inflammatory or suppressive response driven by that particular receptor, while leaving the rest of the immune system intact.
We are passionate about the science underlying the chemoattractant network. More than that, though, we are passionate about the opportunity it holds to provide better medicines for better lives.
|
|
|
|
|
|
3.30
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3.00
|
3.00
|
4.00
|
4.50
|
3.00
|
3.50
|
3.50
|
|
|
|
|
|
|
|
|
|
Aug 28th, 2022 04:39AM
|
Aug 28th, 2022 04:39AM
|
ChemoCentryx
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nasdaq:ccxi
|
https://www.indeed.com/cmp/chemocentryx
|
Aug 27th, 2022 12:00AM
|
Open
|
ChemoCentryx
|
|
Pharmaceutical & Biotechnology
|
ChemoCentryx is a biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer, primarily focused on orphan and rare diseases. We balance our passion for science with the deep-seated belief that patients suffering from serious diseases deserve more than incremental improvements to the length and quality of their lives.
As a clinical-stage company with a broad portfolio of therapeutics in areas such as orphan and rare diseases, chronic kidney disease, immuno-oncology and inflammatory and autoimmune diseases, we push ourselves beyond “good enough” and strive for a totally new way of healing.
Discrete chemokine or chemoattractant receptors play a specific role in how certain diseases progress. So, each of our drug candidates focuses on a specific chemokine or chemoattractant receptor that blocks the negative inflammatory or suppressive response driven by that particular receptor, while leaving the rest of the immune system intact.
We are passionate about the science underlying the chemoattractant network. More than that, though, we are passionate about the opportunity it holds to provide better medicines for better lives.
|
|
|
|
|
|
3.30
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3.00
|
3.00
|
4.00
|
4.50
|
3.00
|
3.50
|
3.50
|
|
|
|
|
|
|
|
|
|
Aug 27th, 2022 03:59AM
|
Aug 27th, 2022 03:59AM
|
ChemoCentryx
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nasdaq:ccxi
|
https://www.indeed.com/cmp/chemocentryx
|
Aug 25th, 2022 12:00AM
|
Open
|
ChemoCentryx
|
|
Pharmaceutical & Biotechnology
|
ChemoCentryx is a biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer, primarily focused on orphan and rare diseases. We balance our passion for science with the deep-seated belief that patients suffering from serious diseases deserve more than incremental improvements to the length and quality of their lives.
As a clinical-stage company with a broad portfolio of therapeutics in areas such as orphan and rare diseases, chronic kidney disease, immuno-oncology and inflammatory and autoimmune diseases, we push ourselves beyond “good enough” and strive for a totally new way of healing.
Discrete chemokine or chemoattractant receptors play a specific role in how certain diseases progress. So, each of our drug candidates focuses on a specific chemokine or chemoattractant receptor that blocks the negative inflammatory or suppressive response driven by that particular receptor, while leaving the rest of the immune system intact.
We are passionate about the science underlying the chemoattractant network. More than that, though, we are passionate about the opportunity it holds to provide better medicines for better lives.
|
|
|
|
|
|
3.30
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3.00
|
3.00
|
4.00
|
4.50
|
3.00
|
3.50
|
3.50
|
|
|
|
|
|
|
|
|
|
Aug 25th, 2022 08:38AM
|
Aug 25th, 2022 08:38AM
|
ChemoCentryx
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nasdaq:ccxi
|
https://www.indeed.com/cmp/chemocentryx
|
Aug 23rd, 2022 12:00AM
|
Open
|
ChemoCentryx
|
|
Pharmaceutical & Biotechnology
|
ChemoCentryx is a biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer, primarily focused on orphan and rare diseases. We balance our passion for science with the deep-seated belief that patients suffering from serious diseases deserve more than incremental improvements to the length and quality of their lives.
As a clinical-stage company with a broad portfolio of therapeutics in areas such as orphan and rare diseases, chronic kidney disease, immuno-oncology and inflammatory and autoimmune diseases, we push ourselves beyond “good enough” and strive for a totally new way of healing.
Discrete chemokine or chemoattractant receptors play a specific role in how certain diseases progress. So, each of our drug candidates focuses on a specific chemokine or chemoattractant receptor that blocks the negative inflammatory or suppressive response driven by that particular receptor, while leaving the rest of the immune system intact.
We are passionate about the science underlying the chemoattractant network. More than that, though, we are passionate about the opportunity it holds to provide better medicines for better lives.
|
|
|
|
|
|
3.30
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3.00
|
3.00
|
4.00
|
4.50
|
3.00
|
3.50
|
3.50
|
|
|
|
|
|
|
|
|
|
Aug 23rd, 2022 10:32AM
|
Aug 23rd, 2022 10:32AM
|
ChemoCentryx
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nasdaq:ccxi
|
https://www.indeed.com/cmp/chemocentryx
|
Aug 21st, 2022 12:00AM
|
Open
|
ChemoCentryx
|
|
Pharmaceutical & Biotechnology
|
ChemoCentryx is a biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer, primarily focused on orphan and rare diseases. We balance our passion for science with the deep-seated belief that patients suffering from serious diseases deserve more than incremental improvements to the length and quality of their lives.
As a clinical-stage company with a broad portfolio of therapeutics in areas such as orphan and rare diseases, chronic kidney disease, immuno-oncology and inflammatory and autoimmune diseases, we push ourselves beyond “good enough” and strive for a totally new way of healing.
Discrete chemokine or chemoattractant receptors play a specific role in how certain diseases progress. So, each of our drug candidates focuses on a specific chemokine or chemoattractant receptor that blocks the negative inflammatory or suppressive response driven by that particular receptor, while leaving the rest of the immune system intact.
We are passionate about the science underlying the chemoattractant network. More than that, though, we are passionate about the opportunity it holds to provide better medicines for better lives.
|
|
|
|
|
|
3.30
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3.00
|
3.00
|
4.00
|
4.50
|
3.00
|
3.50
|
3.50
|
|
|
|
|
|
|
|
|
|
Aug 21st, 2022 12:15PM
|
Aug 21st, 2022 12:15PM
|
ChemoCentryx
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nasdaq:ccxi
|
https://www.indeed.com/cmp/chemocentryx
|
Aug 20th, 2022 12:00AM
|
Open
|
ChemoCentryx
|
|
Pharmaceutical & Biotechnology
|
ChemoCentryx is a biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer, primarily focused on orphan and rare diseases. We balance our passion for science with the deep-seated belief that patients suffering from serious diseases deserve more than incremental improvements to the length and quality of their lives.
As a clinical-stage company with a broad portfolio of therapeutics in areas such as orphan and rare diseases, chronic kidney disease, immuno-oncology and inflammatory and autoimmune diseases, we push ourselves beyond “good enough” and strive for a totally new way of healing.
Discrete chemokine or chemoattractant receptors play a specific role in how certain diseases progress. So, each of our drug candidates focuses on a specific chemokine or chemoattractant receptor that blocks the negative inflammatory or suppressive response driven by that particular receptor, while leaving the rest of the immune system intact.
We are passionate about the science underlying the chemoattractant network. More than that, though, we are passionate about the opportunity it holds to provide better medicines for better lives.
|
|
|
|
|
|
3.30
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3.00
|
3.00
|
4.00
|
4.50
|
3.00
|
3.50
|
3.50
|
|
|
|
|
|
|
|
|
|
Aug 20th, 2022 01:52PM
|
Aug 20th, 2022 01:52PM
|
ChemoCentryx
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nasdaq:ccxi
|
https://www.indeed.com/cmp/chemocentryx
|
Aug 19th, 2022 12:00AM
|
Open
|
ChemoCentryx
|
|
Pharmaceutical & Biotechnology
|
ChemoCentryx is a biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer, primarily focused on orphan and rare diseases. We balance our passion for science with the deep-seated belief that patients suffering from serious diseases deserve more than incremental improvements to the length and quality of their lives.
As a clinical-stage company with a broad portfolio of therapeutics in areas such as orphan and rare diseases, chronic kidney disease, immuno-oncology and inflammatory and autoimmune diseases, we push ourselves beyond “good enough” and strive for a totally new way of healing.
Discrete chemokine or chemoattractant receptors play a specific role in how certain diseases progress. So, each of our drug candidates focuses on a specific chemokine or chemoattractant receptor that blocks the negative inflammatory or suppressive response driven by that particular receptor, while leaving the rest of the immune system intact.
We are passionate about the science underlying the chemoattractant network. More than that, though, we are passionate about the opportunity it holds to provide better medicines for better lives.
|
|
|
|
|
|
3.30
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3.00
|
3.00
|
4.00
|
4.50
|
3.00
|
3.50
|
3.50
|
|
|
|
|
|
|
|
|
|
Aug 19th, 2022 12:15PM
|
Aug 19th, 2022 12:15PM
|
ChemoCentryx
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nasdaq:ccxi
|
https://www.indeed.com/cmp/chemocentryx
|
Aug 18th, 2022 12:00AM
|
Open
|
ChemoCentryx
|
|
Pharmaceutical & Biotechnology
|
ChemoCentryx is a biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer, primarily focused on orphan and rare diseases. We balance our passion for science with the deep-seated belief that patients suffering from serious diseases deserve more than incremental improvements to the length and quality of their lives.
As a clinical-stage company with a broad portfolio of therapeutics in areas such as orphan and rare diseases, chronic kidney disease, immuno-oncology and inflammatory and autoimmune diseases, we push ourselves beyond “good enough” and strive for a totally new way of healing.
Discrete chemokine or chemoattractant receptors play a specific role in how certain diseases progress. So, each of our drug candidates focuses on a specific chemokine or chemoattractant receptor that blocks the negative inflammatory or suppressive response driven by that particular receptor, while leaving the rest of the immune system intact.
We are passionate about the science underlying the chemoattractant network. More than that, though, we are passionate about the opportunity it holds to provide better medicines for better lives.
|
|
|
|
|
|
3.30
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3.00
|
3.00
|
4.00
|
4.50
|
3.00
|
3.50
|
3.50
|
|
|
|
|
|
|
|
|
|
Aug 18th, 2022 03:59AM
|
Aug 18th, 2022 03:59AM
|
ChemoCentryx
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nasdaq:ccxi
|
https://www.indeed.com/cmp/chemocentryx
|
Aug 17th, 2022 12:00AM
|
Open
|
ChemoCentryx
|
|
Pharmaceutical & Biotechnology
|
ChemoCentryx is a biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer, primarily focused on orphan and rare diseases. We balance our passion for science with the deep-seated belief that patients suffering from serious diseases deserve more than incremental improvements to the length and quality of their lives.
As a clinical-stage company with a broad portfolio of therapeutics in areas such as orphan and rare diseases, chronic kidney disease, immuno-oncology and inflammatory and autoimmune diseases, we push ourselves beyond “good enough” and strive for a totally new way of healing.
Discrete chemokine or chemoattractant receptors play a specific role in how certain diseases progress. So, each of our drug candidates focuses on a specific chemokine or chemoattractant receptor that blocks the negative inflammatory or suppressive response driven by that particular receptor, while leaving the rest of the immune system intact.
We are passionate about the science underlying the chemoattractant network. More than that, though, we are passionate about the opportunity it holds to provide better medicines for better lives.
|
|
|
|
|
|
3.30
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3.00
|
3.00
|
4.00
|
4.50
|
3.00
|
3.50
|
3.50
|
|
|
|
|
|
|
|
|
|
Aug 17th, 2022 09:38AM
|
Aug 17th, 2022 09:38AM
|
ChemoCentryx
|
Health Care
|
Pharmaceuticals & Biotechnology
|